2021 TDDW
Section：Cirrhosis & HCC 66.9 years who visited National Taiwan University Hospital were prospectively recruited. Forty eight patients had cancer and 12 had benign strictures. Thirty four patients had cholangiocarcinoma, 3 had gallbladder cancer, 8 had hepatocellular carcinoma, 1 had ampullary cancer and 2 had metastatic cancer. Tissue sampling sensitivity varied according to the different sampling modalities; the highest yield was seen in forceps biopsy whenever before or after biliary dilation. The cumulative sensitivity of triple-tissue sampling in the cancer patients was as follows: sensitivity was 77.1% (before dilation) and 79.2% (after dilation) if atypia was considered malignant and 45.8% (before dilation) and 43.8% (after dilation) if atypia was considered benign. No serious complications occurred from the tissue sampling methods. Conclusions: Tissue sampling sensitivity varied according to the different sampling modalities. Triple tissue-sampling increased sensitivity; Dilation of biliary stricture has no influence on the diagnosis rate of tissue sampling.
㉑
CONCURRENT IMMUNE CHECKPOINT INHIBITOR AND TYROSINE KINASE INHIBITOR THERAPY YIELDS BETTER OUTCOME THAN IMMUNE CHECKPOINT INHIBITOR MONOTHERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA Wei-Fan Hsu1,2,3, Hung-Wei Wang1,3, Hsueh-Chou Lai1,4, Cheng-Kuo Chen5, Po-Heng Chuang1, Ming-Hung Tsai6, Wen-Pang Su1, Sheng-Hung Chen1,3, Wen-Hsin Huang1, Chi-Ying Yang1, Tsung-Yu Tsai1, Wang-De Hsiao1, Chia-Sheng Chu1, Chun-Che Lin1,3, Guan-Tarn Huang1,3, Jaw-Town Lin1,3, Cheng-Yuan Peng1,3 Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan1 Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan2 School of Medicine, China Medical University, Taichung, Taiwan3 School of Chinese Medicine, China Medical University, Taichung, Taiwan4 Division of Gastroenterology & Hepatology, Department of Internal Medicine, Asia University Hospital, Taichung, Taiwan5 Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan6
併用免疫點抑制劑與酪氨酸激酶抑製 劑比單用免疫點抑制劑在晚期肝癌患 者提供更好療效 許偉帆1,2,3 王鴻偉1,3 賴學洲1,4 陳政國5 莊伯恒1 蔡明宏6 蘇文邦1 陳昇弘1,3 黃文信1 楊其穎1 蔡宗佑1 蕭望德1 朱家聲1 林俊哲1,3 黃冠棠1,3 林肇堂1,3 彭成元1,3 中國醫藥大學附設醫院消化醫學中心1 中國醫藥大學生物醫學研究所2 中國醫藥大學醫學系3 中國醫藥大學中醫學系4 亞洲大學附屬醫院肝膽胃腸科5
121
